IP Library Granted Patent US 10,093,916
Granted Patent B2
US 10,093,916 · App. 15/159,345 · Granted Oct 9, 2018

Method for reducing or inactivating viral and microbial content in the processes for the manufacture of pancreatin

Inventors: Kenneth S. Manning (Middleton, WI); Yan Wang (Middleton, WI); Dustin Nielsen (Santa Barbara, CA); Ryan Ruf (De Pere, WI); Colin Crowley (Sun Prairie, WI); Jon Restivo (Stoughton, WI); Dana Spangenberg (Cottage Grove, WI); Karla Anhalt (DeForest, WI); Mark Romich (New Glarus, WI); Anisha Akula (Madison, WI); Carmen Fritz (Sun Prairie, WI)
Assignee: Scientific Protein Laboratories, LLC
C12N9/94A61K9/00A61K31/327A61K35/39A61K38/46C12N7/00C12N2750/10063C12N2750/14363C12N2770/32263
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,093,916
App. No.
15/159,345
Granted
Oct 9, 2018
Kind
B2
Abstract

A method for the reduction or inactivation of viral and microbial content in the manufacturing of pancreatin API is disclosed. The method includes treating animal-derived tissue with peracetic acid to reduce viral activity and bacterial load prior to processing. In particular, the method includes treating porcine pancreas glands with peracteic acid prior to extracting a pancreatin API from the treated glandular tissue.

Claims (17)

1. A method of manufacturing a pancreatin preparation comprising the steps of:

(a) providing a pancreas gland or tissue;

(b) reacting the pancreas gland or tissue with peracetic acid (PAA) in a reaction before enzymatic extraction; and

(c) extracting pancreatin enzymes;

wherein at least one pancreatin enzyme is derived from an animal source to thereby reduce a viral infectivity and reduce a bacterial count in the pancreatin preparation without compromising enzymatic activity.

2. The method of claim 1 , wherein the viral infectivity of non-enveloped viruses in the pancreatin preparation after the reaction is at least 1 log 10 lower compared to the viral infectivity of non-enveloped viruses of the pancreas gland or tissue prior to the reaction with PAA.

3. The method of claim 1 , wherein step (b) further comprises: (i) adding PAA to pancreas gland or tissue, and (ii) incubating the pancreas gland or tissue and PAA for a time sufficient to reduce the viral infectivity.

4. The method of claim 1 , wherein the reaction comprises PAA at a concentration of about 500 ppm to about 20,000 ppm.

5. The method of claim 1 , wherein the reaction comprises PAA at a concentration of about 100 ppm to about 40,000 ppm.

6. The method of claim 1 , wherein the reaction is carried out for about 0.5 minutes to about 30 minutes.

7. The method of claim 1 , wherein the reaction is carried out at a temperature of about 15° C. to about 22° C.

8. The method of claim 1 , wherein the reaction is carried out at a pH of about 1.0 to about 5.5.

9. The method of claim 1 , wherein the method further comprises providing a co-solvent.

10. The method of claim 9 , wherein the co-solvent is an alcohol.

11. The method of claim 1 , wherein the method further comprises extracting a pancreatin active pharmaceutical ingredient (API).

12. The method of claim 11 , wherein the pancreatin API is in the form of a powder.

13. The method of claim 1 , wherein the reaction is carried out within a temperature of 2° C. to about 21° C.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 21, 2016
From: WANG, YAN; MANNING, KENNETH S.; NIELSEN, DUSTIN; RUF, RYAN; CROWLEY, COLIN; RESTIVO, JON; SPANGENBERG, DANA; ANHALT, KARLA; ROMICH, MARK; AKULA, ANISHA; FRITZ, CARMEN
To: SCIENTIFIC PROTEIN LABORATORIES, LLC
Reel/Frame 038976/0788 →
Continuity (2)
Provisional Application 62163779 · May 19, 2015
Related Publication 20170037392A1 · Feb 9, 2017